A Study of Sapanisertib in Relapsed/Refractory NFE2L2-Mutated and Wild-Type Squamous Non-Small Cell Lung Cancer

NCT05275673 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

7

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor decision - funding issues

Conditions

Non-Small Cell Lung Cancer
Squamous Non-small-cell Lung Cancer
Squamous Non-Small Cell Neoplasm of Lung
NFE2L2 Gene Mutation

Interventions

DRUG: sapanisertib

Sponsor

Faeth Therapeutics